The benefits and dangers when genetic testing companies partner with orphan drug developers

September 27, 2017, Mary Ann Liebert, Inc
Credit: Mary Ann Liebert, Inc., publishers

Pharmaceutical companies developing Orphan Drugs are increasingly partnering with direct-to-consumer (DTC) genetic testing firms to identify individuals with rare diseases, in a trend that is raising concerns related to privacy, drug costs, and rising healthcare-related financial burden for consumers. An in-depth look at the enormous positive potential and concomitant dangers of these evolving corporate relationships and their impact on consumers and the healthcare system is published in Genetic Testing and Molecular Biomarkers.

In the article "Direct-to-Consumer Genetic Testing and Orphan Drug Development," coauthors Matthew Mason, James Levenson, MD, and John Quillin, PhD, Virginia Commonwealth University School of Medicine, Richmond, discuss the dynamics and key factors that affect these two sectors of the healthcare industry. The authors examine the science behind DTC and the industry's market growth, how drugs for rare diseases are regulated, the potential for innovation and applying genetic testing results to orphan drug development, and suggested oversight and safeguards needed to protect patients from threats to their privacy and possible price-gouging.

"This paper provides an excellent overview as well as a thoughtful perspective of the interactions between the commercial developers of and the patients and families that they aim to serve who are afflicted with ," says Genetic Testing and Molecular Biomarkers Editor-in-Chief Garth D. Ehrlich, PhD, FAAAS, Professor of Microbiology and Immunology, Executive Director, Center for Genomic Sciences and Center for Advanced Microbial Processing, Institute for Molecular Medicine and Infectious Disease, Drexel College of Medicine (Philadelphia, PA).

Explore further: Are biobank donor families worried about a confidentiality breach?

More information: Matthew Mason et al, Direct-to-Consumer Genetic Testing and Orphan Drug Development, Genetic Testing and Molecular Biomarkers (2017). DOI: 10.1089/gtmb.2017.0087

Related Stories

Are biobank donor families worried about a confidentiality breach?

April 5, 2017
A new study examines how well families that donate tissue to a biobank—or decide not to donate—understand the risk and implications of a potential confidentiality breach. The technology to acquire genome sequence data ...

A genetic variation may increase tuberculosis susceptibility

July 21, 2017
Researchers have shown that a single nucleotide change in a gene that affects production of hepcidin—a peptide involved in inflammation, immunity, and control of iron levels—is associated with greater susceptibility to ...

What's missing from current methods for genetic screening of sperm donors?

April 26, 2016
U.S. sperm banks perform genetic testing to screen for and disqualify carriers of a limited number of recessive disease mutations, but more comprehensive and affordable DNA-based screening methods are now available that can ...

Pharmaceutical companies are profiting from rare diseases: study

October 21, 2016
Incentives intended to stimulate the development of more treatments for rare diseases are being exploited to boost the profits of pharmaceutical companies, new research led by Bangor University shows.

New metabolomic screening method detects multiple inborn errors of metabolism in urine

November 3, 2016
Analysis of a single urine sample using a metabolomics-based screening approach can identify multiple different inborn errors of metabolism (IEMs), facilitating early disease detection and rapid initiation of treatment, as ...

Ethics complicate clinical interpretation and reporting of human genome sequence results

April 3, 2017
Medical use of a patient's genomic sequence information can improve diagnostic capabilities and enable personalized therapies, but technical and practical barriers to understanding the clinical implications of sequence data ...

Recommended for you

Thousands of unknown DNA changes in the developing brain revealed by machine learning

September 24, 2018
Unlike most cells in the rest of our body, the DNA (the genome) in each of our brain cells is not the same: it varies from cell to cell, caused by somatic changes. This could explain many mysteries—from the cause of Alzheimer's ...

Mitochondrial diseases could be treated with gene therapy, study suggests

September 24, 2018
Researchers have developed a genome editing tool for the potential treatment of mitochondrial diseases: serious and often fatal conditions which affect 1 in 5,000 people.

Height may be risk factor for varicose veins, study finds

September 24, 2018
The taller you are, the more likely you are to develop varicose veins, according to a study led by Stanford University School of Medicine researchers that examined the genes of more than 400,000 people in search of clues ...

How to edit your mitochondria

September 24, 2018
Mitochondrial genetic engineering is the adaptation of genetic engineering techniques to specific mitochondrial problems. Although it is not common to be born with severe mitochondrial issues, we will all eventually have ...

Researchers identify new genetic disorder

September 21, 2018
Researchers from Michigan State University College of Human Medicine and physicians from Spectrum Health have identified for the first time in a human patient a genetic disorder only previously described in animal models.

Test could detect patients at risk from lethal fungal spores

September 20, 2018
Scientists at The University of Manchester have discovered a genetic mutation in humans linked to a 17-fold increase in the amount of dangerous fungal spores in the lungs.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.